Please login to the form below

Not currently logged in
Email:
Password:

Dr Edward Browne joins Sygnature Discovery

He becomes associate director of drug metabolism and pharmacokinetics

Sygnature Discovery Dr Edward BrowneNottingham, UK-based Sygnature Discovery has expanded its drug metabolism and pharmacokinetics (DMPK) team with the appointment of Dr Edward Browne as associate director.

Dr Browne (pictured right) moves to the drug discovery service provider from GlaxoSmithKline, where he most recently served as head of DMPK for its Singapore operations.

He first joined GSK as a bioanalytical scientist in 2000, before working at Simbec Research in a similar post.

In 2005, Dr Browne re-joined GSK, becoming a team leader in its neural pathways discovery performance unit in Singapore before taking on increasingly senior roles.

Dr Timothy Schulz-Utermoehl, director of DMPK at Sygnature Discovery, said: “I am delighted to welcome Ed to the team here at Sygnature.

“Ed brings significant DMPK and drug discovery experience to our rapidly expanding department as we continue to build our CNS expertise and large molecule bio analysis.”

24th October 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics